In this proof-of-concept study, Maja Skov Kragsnaes and colleagues evaluated the efficacy and safety of TFA in people with psoriatic arthritis (PSA). PsA is an inflammatory arthritis that causes a person’s joints to become stiff and painful. It is often found in people with psoriasis skin disease, and there is also a link between PSA and inflammatory bowel disease or gastrointestinal symptoms.
This double-blind, parallel, simulation-controlled superiority trial randomly assigned 31 adults with active peripheral PsAd despite continued methotrexate treatment to a gastroscopically guided FMT procedure or simulated duodenal transplantation. The transplants (50 g stool) came from one of four healthy and anonymous stool donors. The main endpoint of efficacy was the proportion of participants who experienced treatment failure, which was defined as requiring intensification of treatment for 26 weeks and safety was monitored throughout the period.
The results proved it treatment failure occurred more frequently in the FMT group than in the simulated group (60% versus 19%, and improvement in function was also in favor of the simulacrum. No serious adverse events were observed.
Kragsnaes MS, et al. Efficacy and safety of fecal microbiota transplantation for active peripheral psoriatic arthritis: a randomized controlled trial. Presented at EULAR 2021. Abstract OP0010.
Provided by the European Alliance of Associations for Rheumatology
Citation: Fecal microbiota transplantation for active peripheral psoriatic arthritis has no benefit (2021, June 18) recovered on June 18, 2021 from https://medicalxpress.com/news/2021-06-fecal-microbiota -transplantation-peripheral-psoriatic.html
This document is subject to copyright. Apart from any fair treatment for private study or research purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.